Progress in refining the clinical management of cancer of unknown primary in the molecular era

Nature Reviews Clinical Oncology, Published online: 29 April 2020; doi:10.1038/s41571-020-0359-1Despite improvements in diagnostic strategies, cancer of unknown primary — metastatic cancer in patients in whom the primary tumour remains undetected — continues to account for around 1–2% of all cancers. In this Review, Rassy and Pavlidis discuss insights into the biology of CUP and shifts in the clinical management of this enigmatic disease entity in the era of precision medicine.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research